First Twenty-Five Percent of Subjects in Provectus’ Phase 2 Melanoma Clinical Trial Treated
News Jul 08, 2008
Provectus Pharmaceuticals, Inc. has announced that the first twenty-five percent (20 of 80) of melanoma subjects have been treated in Provectus Pharmaceuticals’ Phase 2 clinical trial of PV-10.
Additional subjects are being evaluated for eligibility for entrance into the trial or are awaiting treatment at the two active centers in Brisbane and Sydney, Australia.
In addition, Provectus anticipates opening the first United States site for the trial in the very near future. Currently, Provectus is also sponsoring Phase 2 trials for psoriasis and atopic dermatitis in New York and Florida.
In Australia, the trials are currently being conducted at the Sydney Melanoma Unit under the supervision of John F Thompson, MD, and at the Princess Alexandra Hospital in Brisbane, Queensland, under Mark Smithers, MD.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Clinical And Medical Microbiology
Sep 10 - Sep 11, 2018